AR063707A1 - Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden. - Google Patents
Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.Info
- Publication number
- AR063707A1 AR063707A1 ARP070103989A ARP070103989A AR063707A1 AR 063707 A1 AR063707 A1 AR 063707A1 AR P070103989 A ARP070103989 A AR P070103989A AR P070103989 A ARP070103989 A AR P070103989A AR 063707 A1 AR063707 A1 AR 063707A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkylene
- hydrogen
- activity
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Composiciones farmacéuticas que comprenden a los compuestos mencionados, junto con al menos un vehículo aceptable para uso farmacéutico seleccionado entre vehículos, coadyuvantes y excipientes. Estos compuestos se utilizan en el tratamiento de enfermedades que responden a la inhibición de la actividad de Btk y/o la actividad de la célula. Reivindicación 1: Un compuesto seleccionado entre los compuestos de fórmula 1: y sales aceptables para uso farmacéutico, quelatos, complejos no covalentes, prodrogas y mezclas de los mismos, en donde R se selecciona entre arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; R4 se selecciona entre hidrógeno, alquilo inferior opcionalmente sustituido, alcoxi inferior opcionalmente sustituido, halo, y hidroxi. R21 y R22 se seleccionan en forma independiente entre hidrógeno y alquilo inferior opcionalmente sustituido; R16 se selecciona entre hidrógeno, ciano, cicloalquilo opcionalmente sustituido, y alquilo inferior opcionalmente sustituido; A se selecciona entre heteroarilo de 5 miembros opcionalmente sustituido, piridazinilo opcionalmente sustituido, pirimidinilo opcionalmente sustituido; y pirazinilo opcionalmente sustituido, L se selecciona entre alquileno C0-4 opcionalmente sustituido, -O-alquileno C0-4 opcionalmente sustituido, -alquileno C0-4(SO)-, -alquileno C0-4(SO2) y -alquileno C0-4(C=O)-; y G se selecciona entre hidrógeno, halo, hidroxi, alcoxi, nitro, alquilo opcionalmente sustituido, amino opcionalmente sustituido, carbamimidoilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, y heteroarilo opcionalmente sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84383306P | 2006-09-11 | 2006-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063707A1 true AR063707A1 (es) | 2009-02-11 |
Family
ID=39184519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103989A AR063707A1 (es) | 2006-09-11 | 2007-09-10 | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden. |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP2079726B1 (es) |
| JP (1) | JP5563301B2 (es) |
| KR (1) | KR101444481B1 (es) |
| CN (1) | CN101605778A (es) |
| AR (1) | AR063707A1 (es) |
| AT (1) | ATE496909T1 (es) |
| AU (1) | AU2007296563B2 (es) |
| BR (1) | BRPI0716914A2 (es) |
| CA (1) | CA2661951C (es) |
| CL (1) | CL2007002642A1 (es) |
| CO (1) | CO6180464A2 (es) |
| CR (1) | CR10709A (es) |
| DE (1) | DE602007012281D1 (es) |
| EC (1) | ECSP099238A (es) |
| ES (1) | ES2363269T3 (es) |
| IL (1) | IL197264A0 (es) |
| MA (1) | MA31276B1 (es) |
| MX (1) | MX2009002651A (es) |
| NO (1) | NO20091426L (es) |
| PE (1) | PE20081370A1 (es) |
| RU (1) | RU2009113692A (es) |
| TW (1) | TWI398439B (es) |
| WO (1) | WO2008033857A2 (es) |
| ZA (1) | ZA200901634B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR063706A1 (es) * | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| CA2701275C (en) * | 2007-10-23 | 2016-06-21 | F. Hoffmann-La Roche Ag | Kinase inhibitors |
| US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| ES2554615T3 (es) * | 2008-05-06 | 2015-12-22 | Gilead Connecticut, Inc. | Amidas sustituidas, método de preparación y utilización como inhibidores de Btk |
| CA2728016C (en) | 2008-06-24 | 2017-02-28 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
| PE20110164A1 (es) | 2008-07-02 | 2011-03-28 | Hoffmann La Roche | Nuevas fenilpirazinonas como inhibidores de quinasa |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| JP6575950B2 (ja) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異 |
| ES2619125T3 (es) | 2013-04-25 | 2017-06-23 | Beigene, Ltd. | Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa |
| CN104177338B (zh) * | 2013-05-22 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类布鲁顿激酶抑制剂 |
| JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｐｄ−１抗体並びにその治療及び診断のための使用 |
| CA2929918C (en) * | 2013-12-05 | 2018-01-23 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| JP6526189B2 (ja) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用 |
| WO2016079669A1 (en) * | 2014-11-19 | 2016-05-26 | Novartis Ag | Labeled amino pyrimidine derivatives |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP4141002A1 (en) | 2015-11-19 | 2023-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA44075A (fr) * | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| PL3394033T3 (pl) | 2015-12-22 | 2021-05-31 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
| SG10202110874TA (en) | 2016-06-07 | 2021-11-29 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| MX2018016273A (es) | 2016-06-20 | 2019-07-04 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN109563099B (zh) | 2016-08-16 | 2023-02-03 | 百济神州有限公司 | 一种化合物的晶型、其制备和用途 |
| AU2017313085A1 (en) | 2016-08-19 | 2019-03-14 | Beigene Switzerland Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| JP2019529419A (ja) | 2016-09-19 | 2019-10-17 | エムイーアイ ファーマ，インク． | 併用療法 |
| MD3558990T2 (ro) | 2016-12-22 | 2023-02-28 | Incyte Corp | Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1 |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| CN110582493B (zh) | 2016-12-22 | 2024-03-08 | 因赛特公司 | 作为免疫调节剂的苯并噁唑衍生物 |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| EA201992253A1 (ru) | 2017-03-23 | 2020-03-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| SG11202009440WA (en) | 2018-03-30 | 2020-10-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| DK3790877T3 (da) | 2018-05-11 | 2023-04-24 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| US11401279B2 (en) | 2019-09-30 | 2022-08-02 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| TW202120504A (zh) | 2019-11-11 | 2021-06-01 | 美商英塞特公司 | Pd-1/pd-l1 抑制劑之鹽及結晶型 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| AU2021373044A1 (en) | 2020-11-06 | 2023-06-08 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU768201B2 (en) * | 1999-01-22 | 2003-12-04 | Amgen, Inc. | Kinase inhibitors |
| JP2005255675A (ja) * | 2004-02-09 | 2005-09-22 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| RU2423351C2 (ru) * | 2004-12-16 | 2011-07-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний |
-
2007
- 2007-09-10 AR ARP070103989A patent/AR063707A1/es unknown
- 2007-09-10 PE PE2007001210A patent/PE20081370A1/es not_active Application Discontinuation
- 2007-09-11 MX MX2009002651A patent/MX2009002651A/es not_active Application Discontinuation
- 2007-09-11 DE DE602007012281T patent/DE602007012281D1/de active Active
- 2007-09-11 JP JP2009527626A patent/JP5563301B2/ja active Active
- 2007-09-11 WO PCT/US2007/078185 patent/WO2008033857A2/en active Application Filing
- 2007-09-11 AT AT07842267T patent/ATE496909T1/de not_active IP Right Cessation
- 2007-09-11 CN CNA200780041899XA patent/CN101605778A/zh active Pending
- 2007-09-11 EP EP07842267A patent/EP2079726B1/en active Active
- 2007-09-11 KR KR1020097007473A patent/KR101444481B1/ko active IP Right Grant
- 2007-09-11 CA CA2661951A patent/CA2661951C/en not_active Expired - Fee Related
- 2007-09-11 TW TW096133935A patent/TWI398439B/zh not_active IP Right Cessation
- 2007-09-11 ES ES07842267T patent/ES2363269T3/es active Active
- 2007-09-11 RU RU2009113692/04A patent/RU2009113692A/ru not_active Application Discontinuation
- 2007-09-11 BR BRPI0716914-0A patent/BRPI0716914A2/pt not_active Application Discontinuation
- 2007-09-11 AU AU2007296563A patent/AU2007296563B2/en not_active Ceased
- 2007-09-11 CL CL200702642A patent/CL2007002642A1/es unknown
-
2009
- 2009-02-26 IL IL197264A patent/IL197264A0/en unknown
- 2009-03-06 ZA ZA200901634A patent/ZA200901634B/xx unknown
- 2009-04-01 CO CO09033749A patent/CO6180464A2/es not_active Application Discontinuation
- 2009-04-03 CR CR10709A patent/CR10709A/es unknown
- 2009-04-06 MA MA31767A patent/MA31276B1/fr unknown
- 2009-04-07 NO NO20091426A patent/NO20091426L/no not_active Application Discontinuation
- 2009-04-07 EC EC2009009238A patent/ECSP099238A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008033857A2 (en) | 2008-03-20 |
| ZA200901634B (en) | 2009-12-30 |
| BRPI0716914A2 (pt) | 2013-11-05 |
| MX2009002651A (es) | 2009-03-26 |
| RU2009113692A (ru) | 2010-10-20 |
| NO20091426L (no) | 2009-06-10 |
| WO2008033857A3 (en) | 2008-06-05 |
| TW200829567A (en) | 2008-07-16 |
| EP2079726B1 (en) | 2011-01-26 |
| ES2363269T3 (es) | 2011-07-28 |
| CL2007002642A1 (es) | 2008-07-18 |
| CO6180464A2 (es) | 2010-07-19 |
| AU2007296563B2 (en) | 2013-01-10 |
| AU2007296563A1 (en) | 2008-03-20 |
| IL197264A0 (en) | 2009-12-24 |
| KR20090074192A (ko) | 2009-07-06 |
| CN101605778A (zh) | 2009-12-16 |
| EP2079726A2 (en) | 2009-07-22 |
| KR101444481B1 (ko) | 2014-09-24 |
| JP5563301B2 (ja) | 2014-07-30 |
| DE602007012281D1 (de) | 2011-03-10 |
| CA2661951C (en) | 2014-11-18 |
| CA2661951A1 (en) | 2008-03-20 |
| ECSP099238A (es) | 2009-07-31 |
| CR10709A (es) | 2009-07-14 |
| MA31276B1 (fr) | 2010-04-01 |
| TWI398439B (zh) | 2013-06-11 |
| PE20081370A1 (es) | 2008-11-28 |
| JP2010502750A (ja) | 2010-01-28 |
| ATE496909T1 (de) | 2011-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063707A1 (es) | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden. | |
| AR063706A1 (es) | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. | |
| ATE442349T1 (de) | Diacylglycerol-acyltransferase-hemmer | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| SE0302486D0 (sv) | Novel compounds | |
| UY29963A1 (es) | Compuestos terapéuticos: piridinas y pirazinas como andamios | |
| ECSP055774A (es) | Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| BRPI0813244B8 (pt) | compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário | |
| NO20085060L (no) | Triazolpyrazinderivater anvendelige som anti-cancermidler | |
| SE0302324D0 (sv) | Novel compounds | |
| NI201000085A (es) | Derivados bis - (sulfonilamino) en terapia 066. | |
| AR039672A1 (es) | Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat) | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| EA200870117A1 (ru) | Азаиндоловые ингибиторы аурора-киназ | |
| BRPI0408347B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
| UY28144A1 (es) | Agentes terapéuticos | |
| EA200801608A1 (ru) | Производные бензимидазолонкарбоновой кислоты | |
| AR057033A1 (es) | Tigeciclina y metodos para preparar 9-nitrominociclina | |
| ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
| TW200643013A (en) | Pyrazoles | |
| ECSP066947A (es) | Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias | |
| SE0302323D0 (sv) | Novel compounds | |
| BRPI0714885B8 (pt) | compostos terapêuticos e seu uso | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |